Enrollment and randomization. Participants were recruited between 10 February and 26 April 2021. Of 422 participants who were eligible to receive camostat in the study, 167 were allocated to the camostat agent group; 113 of those were randomized to camostat and 54 to oral placebo matching camostat. Of 255 allocated to the other agent groups, 57 participants who had been randomized to placebo from another phase 2 agent group, together with the 54 participants who received placebo matching camostat, formed the pooled placebo group for the primary analysis. The participants who received at least 1 dose of study treatment (109 in the camostat and 107 in the placebo arms) formed the mITT population. Abbreviation: mITT, modified intent-to-treat.